Marianne De Backer, M.Sc., Ph.D., MBA, serves as the Chief Executive Officer and Director of Vir Biotechnology. Since joining in April 2023, Dr. De Backer has led the company through a critical strategy evolution sharpening its focus in infectious disease and applying its scientific expertise to critical unmet needs in oncology. Under Dr. De Backer’s leadership Vir Biotechnology has a robust pipeline of late-stage assets in hepatitis delta and hepatitis B and three T-cell engagers in earlier development tackling a range of solid tumors. The company also applies its world-class immunology expertise and leading data science capabilities to rapidly advance a research pipeline in service of its mission to power the immune system to transform lives.
Prior to joining Vir Biotechnology, Dr. De Backer has accelerated the growth and impact of large pharmaceutical companies and their portfolios, and helped bring important new therapeutics to patients around the world. Throughout her career, Dr. De Backer has been recognized for her leadership and contributions to the biopharma industry. She currently serves on the Board of Directors for the Biotechnology Innovation Organization.
Dr. De Backer previously served as a member of the Executive Committee, and Executive Vice President and Global Head of Strategy, Business Development & Licensing of the Bayer AG Pharmaceuticals division. During her tenure at Bayer, she spearheaded the Company’s external innovation, resulting in more than 50 new alliances and company acquisitions. She also served on the Board of Directors of Bluerock Therapeutics, Asklepios Biopharmaceutical, Vividion Therapeutics, KronosBio and Arrowhead Therapeutics.
From 1991 through 2019, at Johnson & Johnson, Dr. De Backer held global business and corporate development roles, including the position of Head and Vice President of M&A Operations and Divestitures globally for the Pharmaceuticals Group. Prior to that, she led the launch of two medicines in neuroscience and immunology. Dr. De Backer started her career in drug discovery research and is an inventor on seven patents.
Dr. De Backer received her Master of Business Administration degree from Erasmus University Rotterdam, The Netherlands. She holds a Master of Science in Molecular Biology from Vrije Universiteit, Brussels; and Master of Science in Engineering Biochemistry and a Ph.D. in Biotechnology, from Ghent University, Belgium. She currently serves as a non-executive Director on the Board of the Gladstone Foundation.
What is Marianne De Backer's net worth?
The estimated net worth of Marianne De Backer is at least $4.71 million as of April 3rd, 2025. Ms. De Backer owns 769,505 shares of Vir Biotechnology stock worth more than $4,709,371 as of April 26th. This net worth approximation does not reflect any other investments that Ms. De Backer may own. Additionally, Ms. De Backer receives an annual salary of $4,470,000.00 as CEO & Director at Vir Biotechnology. Learn More about Marianne De Backer's net worth.
How old is Marianne De Backer?
What is Marianne De Backer's salary?
How do I contact Marianne De Backer?
The corporate mailing address for Ms. De Backer and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at ir@vir.bio. Learn More on Marianne De Backer's contact information.
Has Marianne De Backer been buying or selling shares of Vir Biotechnology?
During the last quarter, Marianne De Backer has sold $474,286.40 in shares of Vir Biotechnology stock. Most recently, Backer Marianne De sold 79,712 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a transaction totalling $474,286.40. Following the completion of the sale, the chief executive officer now directly owns 769,505 shares of the company's stock, valued at $4,578,554.75. Learn More on Marianne De Backer's trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Marianne De Backer (CEO & Director), Vanina de Verneuil (EVP, General Counsel and Corporate Secretary), Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 10 times. They sold a total of 130,587 shares worth more than $972,578.37. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 79,712 shares worth more than $474,286.40. Insiders at Vir Biotechnology own 15.6% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 4/3/2025.
